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Abstract
Background: To update community-based prevalence values for Polymyalgia Rheumatic (PMR) and Giant Cell Arteritis
(GCA) using case record review supplemented by population survey and subsequent clinical review.
Methods: Clinical data were obtained from case records of a large primary care practice in Norfolk, UK and
reviewed for diagnoses of GCA and PMR. In addition postal survey was carried out to capture potentially undiagnosed
cases within the practice population. Those screening positive for potential diagnoses of GCA and PMR were invited for
clinical review. A cumulative prevalence estimate was subsequently calculated on those diagnosed within the GP
practice and subsequently on those fulfilling the various published classification criteria sets. The date of the
database lock and mail merge was March 2013.
Results: Through detailed systematic review of 5,159 GP case records, 21 patients had a recorded diagnosis of
GCA and 117 had PMR.No new cases were identified among 2,227 completed questionnaires returned from the
population survey of a sample of 4,728. The resulting cumulative prevalence estimate in those aged ≥ 55 years
meeting the ACR classification criteria set for GCA was 0.25 % (95 % CI 0.11 to 0.39 %) and for five published
criteria sets for PMR ranged from 0.91 to 1.53 % (95 % CI ranges 0.65 %, 1.87 %). The prevalence of both
conditions was higher in women than in men and in older age groups.
Conclusion: This study provides the first UK prevalence estimate of GCA and PMR in over 30 years and is the first
to apply classification criteria sets.
Background
Giant Cell Arteritis (GCA) is a vasculitis that predom-
inantly affects large arteries and has substantial mor-
bidity with permanent visual loss occurring in up to
35 % of patients [1, 2]. Polymyalgia rheumatica (PMR)
is an inflammatory condition of unknown aetiology
causing pain and stiffness in the shoulder and hip girdle
[3, 4]. Both conditions overlap and are rarely diagnosed
in individuals under 50 years of age, with older age be-
ing part of many of the classification criteria sets for
both diseases.
Their prevalence is poorly reported globally. The only
prevalence study of GCA and PMR from the UK to
date was conducted in 1985 by Kyle et al. in a single
Cambridgeshire practice [5] and has not been repeated.
The resultant prevalence estimate of GCA was 1.23 %
for those aged ≥ 65 years [5] and for GCA combined
with PMR was 3.5 % [5]. The Kyle et al. study pre-dates
the current ACR classification criteria set and failed to
include participants younger than 65 years. Both condi-
tions are commoner in older age groups and the life-
expectancy of the UK population is increasing [6].
More recent data from Europe and the USA have given
widely varied prevalence estimates, with an over 30-fold
discrepancy (see Table 1). Data from the Mayo clinic
from all incident cases of GCA from Olmsted County
(years 1950 to 1999), revealed 173 cases of GCA in those
aged ≥ 50 years. This resulted in a prevalence estimate for
GCA of 0.23 % and for PMR of 0.74 % (95 % CI 0.67 to
0.81) [7–9]. Data from Germany from a questionnaire sent
to hospital departments and insurance companies in 2006
* Correspondence: maxyates@doctors.org.uk
1Department of Rheumatology, Norfolk and Norwich University Hospital,
Colney Lane, Norwich NR4 7UY, UK
2Norwich Medical School, Bob Champion Research and Education Building,
University of East Anglia, Norwich, Norfolk NR4 7UQ, UK
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yates et al. BMC Musculoskeletal Disorders  (2016) 17:285 
DOI 10.1186/s12891-016-1127-3
revealed a prevalence for GCA of 0.04 % (95 % CI 0.04 to
0.05) [10].
Accurate prevalence estimates for GCA and PMR en-
able the burden of disease and associated costs to the
health service to be calculated and development of ap-
propriate services to manage this group of patients. The
aim of this study was to provide contemporary estimates
of prevalence in a representative UK community sample
using current classification criteria sets.
Methods
Design
General Practice case record review, supplemented by
subsequent postal survey and sampling involving clinical
examination by a rheumatologist.
Setting
Drayton and St Faith’s Medical Practice, a dispensing
medical practice situated to the north-west of the city of
Norwich, UK. The practice includes urban and rural
areas, residential suburbs and extends into outlying vil-
lages. The practice provides care for approximately
13,000 individuals. In the UK it is usual for patients to
register with their local practice and this practice falls
within the catchment area of Broadland district in the
county of Norfolk. The five electoral wards covered by
the practice have a combined population (from the 2011
Census) of 15,102 of whom 5,108 (34 %) were aged
≥55 years and 2,983 (20 %) were aged ≥65 years. The
practice is representative of the Norfolk population in
terms of ethnicity, gender ratio and age structure (36 %
of the Norfolk population are aged ≥55 years).
Database search
Cases of GCA and PMR were identified through a GP data-
base review. All individuals aged ≥ 55 years were included.
An age cut-off of 55 years was used for pragmatic reasons
as cases of GCA and PMR are rare at younger ages. Read
code analysis (GCA: G755., G7550, G7551, G7552, G755z
and PMR: N20.., N200.) and key word searches (polymyal-
gia rheumatica, giant cell arteritis, temporal arteritis) were
performed to interrogate the electronic GP register. To
satisfy a GP diagnosis of either GCA or PMR, patients
needed to have received treatment with glucocorticoids
AND a diagnosis that was not later refuted. Those whose
diagnosis was later refuted were considered not to have the
conditions. The search, and subsequent database lock and
mail merge was carried out on the 8th March 2013.
Case classification
GCA
To be classified as GCA, cases were required to fulfil the
1990 ACR criteria set (at least 3 from the following 5): 1.
Age at disease onset > =50 years (Development of symptoms
or findings beginning at age 50 or older); 2. New headache
(New onset of or new type of localised pain in the head); 3.
Temporal artery abnormality (Temporal artery tenderness
to palpation or decreased pulsation, unrelated to arterio-
sclerosis of cervical arteries); 4. Elevated erythrocyte sedi-
mentation rate (Erythrocyte sedimentation rate > =50 mm/
Table 1 Published estimates for GCA and PMR prevalence
Author Country; survey type; age threshold GCA and PMR prevalence Classification
Kyle et al.
1985 [5]
UK; GP practice based survey; ≥ 65 years. GCA: 1.23 %
(95 % CI 0.38 to 2.08)
PMR: 1.69 %
(95 % CI 0.70 to 2.68)
GCA: Jones and Hazleman
PMR: Jones and Hazleman
Koboyashi et al.
2003 [20]
Japan; Hospital only treated patients in
1997; ≥50 years
GCA: 0.002 % GCA: ACR 1990
Lawrence et al.
2008 [7]
Salvarni et al.,
1999 [8].
Doran et al.
2002 [9].
USA; Olmsted County survey of cumulative
incidence 1950–1999; ≥50 years
GCA: 0.28 %
(95 % CI, 0.19–0.27) -
PMR: 0.74 % (95 % CI, 0.67–0.81)
GCA: ACR 1990
PMR: Doran et al.
Mohammad et
al. 2011 [21]
Skåne,Sweden; survey of cumulative incidence
1997 – 2010; ≥50 years
GCA: 0.11 %
(95 % CI, 0.10–0.12).
GCA: Temporal artery biopsy positive only
Herlyn et al.
2014 [10]
Germany; Survey of hospitals, private physicians and
insurance companies in 2006; ≥50 years
GCA: 0.04 %
(95 % CI 0.04 to 0.05)
GCA: ACR 1990
Salaffi et al.
2005 [24]
Italian MAPPING study; population survey; age
≥65 years
PMR: 0.37 %
(95 % CI 0.29–0.44)
PMR: Bird et al.
Bernatsky et al.
2009 [23]
Canada; hospital record survey, cumulative incidence
1995–2006; ≥50 years
PMR: 0.64 % (urban);
0.86 % (rural)
PMR: Physician billing twice within
2 months or stated on hospital discharge.
Pamuk et al.
2009 [19]
Turkey. Single rheumatology department in a tertiary
referral centre, cumulative incidence, ≥50 years
PMR and GCA: 0.02 % GCA: ACR 1990
PMR: Chuang et al.
Yates et al. BMC Musculoskeletal Disorders  (2016) 17:285 Page 2 of 9
h by the Westergren method); 5. Abnormal artery biopsy
(Biopsy specimen with artery showing vasculitis charac-
terised by a predominance of mononuclear cell infiltration
or granulomatous inflammation, usually with multinucle-
ated giant cells) [11].
PMR
There are several classification criteria sets for PMR
[12–17] sharing some common features (Table 2). Key
information (clinical features and results of inflamma-
tory markers) were extracted from patients’ case records
to enable classification by five distinct criteria sets: Bird
[12]; Chuang [13]; Healey [14]; Jones and Hazleman
[15], and Doran [9]. The newer criteria published in
2012 have a point scoring system and incorporate the re-
sults of either rheumatoid factor or anti-CCP antibody
[17]. However, in the UK, rheumatoid factor (RhF) and
anti-CCP antibody (ACPA) are not uniformly requested
in patients with possible PMR [18] and these criteria
were not used.
Sampling frame
To capture potentially undiagnosed cases, the entire
practice population aged ≥ 55 years was surveyed using a
questionnaire specifically designed to detect cardinal fea-
tures of GCA and PMR. Patients were excluded if they
had dementia, a terminal illness, were living in a nurs-
ing home or had previously informed the practice they
did not wish to take part in research. Non-responders
were sent a reminder invitation and questionnaire after
three months.
Questionnaire development
No questionnaire currently exists for classifying people
with GCA or PMR for diagnostic purposes. In order to
capture undiagnosed cases, we required an instrument
sensitive to the detection of the broadest possible range of
symptoms of PMR and GCA. The diagnosis could be con-
firmed or refuted by later applying clinical judgement dur-
ing a patient visit. A new questionnaire was developed by
adapting the 1985 questionnaire used by Kyle et al. [5], to
Table 2 Classification Criteria for Polymyalgia Rheumatica
Authors & Year Proposed Criteria Requirement for Classification
Bird et al. (1979) Age ≥65 years
Bilateral shoulder pain and stiffness; acute or subacute onset (<2
weeks); morning stiffness >1 h depression and/or weight loss; bilateral
tenderness in upper arm muscles
ESR >40 mm/h
Any three, or any one plus temporal artery abnormality
(including decreased pulsation, tenderness, beading or
bruit).
Jones and
Hazelman (1981)
Shoulder and pelvic girdle pain; morning stiffness >1 h; exclusion of
rheumatoid arthritis or other inflammatory arthropathy, myopathy,
malignancy
ESR >30 mm/h or CRP >6 mg/L
Rapid response to corticosteroids
All criteria must be met
Chuang et al.
(1982)
Age ≥50 years
>1 month bilateral aching and stiffness of at least two of the following
areas: Neck or torso, shoulders or proximal arms, hips or proximal
thighs; exclusion of other causes
ESR >40 mm/h
All criteria must be met
Healey and
Wilske (1984)
Age≥ 50 years
>1 month of neck, shoulder, or pelvic girdle pain (any two areas);
morning stiffness >1 h; exclusion of other diagnoses
ESR ≥40 mm/h
Rapid response to daily, low-dose steroid therapy (i.e., prednisolone
≤20 mg)
All criteria must be met
Doran et al.
(2002)
Age≥ 50 years;
Bilateral aching and morning stiffness (lasting≥ 30 min) persisting for
at least 1 month and involving 2 of the following areas: neck or torso,
shoulders or proximal regions of the arms, and hips or proximal
aspects of the thighs
ESR > 40 mm/h OR rapid response to corticosteroids
All criteria must be met
Dasgupta et al.
(2012)
Morning stiffness≥ 45 min (2 points); Hip pain, limited range of
movement (1 point) Absence of other joint pain (1 point)
Normal RhF or ACPA (2 points)
Ultrasound criteria: at least 1 shoulder with subdeltoid bursitis and/or
biceps tenosynovitis and/or glenohumeral synovitis AND at least 1 hip
with synovitis and/or trochanteric bursitis (1 point); both shoulders
with subdeltoid bursitis, bicep tenosynovitis or glenohumeral synovitis
(1 point)
All patients must be: Age ≥50 years, have bilateral
shoulder aching and abnormal ESR/CRP
Scoring algorithm without ultrasound score of 4 needed
– with ultrasound score of 5 needed
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include the 1990 ACR criteria set [11] and informed by a
review of the nature and frequency of symptoms reported
from GCA and PMR cohorts published in the literature.
This questionnaire captured the following symptoms:
headache, visual disturbance, scalp tenderness, symptoms
suggestive of jaw claudication, shoulder pain and stiffness,
myalgia, weight loss, general malaise, and important po-
tential discriminative symptoms of migraine. The ques-
tionnaire also asked participants whether they had ever
been diagnosed by their GP with either GCA or PMR. Its
face validity was confirmed in a hospital sample of ten pa-
tients with GCA and or PMR, and among three rheuma-
tologists and two rheumatology nurse practitioners
specialising in vasculitis.
Clinical review of potential cases
Based on their questionnaire responses, all participants
who answered positively to questions on jaw claudica-
tion AND scalp tenderness AND visual disturbance,
with or without the presence of headache and who were
not already known to the practice as having a diagnosis
of GCA, were invited for clinical review by a rheuma-
tologist. This group was considered as having a high
likelihood of having a diagnosis of GCA. Those answer-
ing positively to one or more questions were considered
at intermediate likelihood of having GCA or PMR and a
random sample (Excel Microsoft Corporation random
number generator) of these was invited for clinical re-
view. Those included in the random sample would be
expected to contain potentially undiagnosed cases of
PMR or GCA.
Sample size calculation
A sample size of 4,000 allowed the detection of an antic-
ipated prevalence of 0.3 % for GCA with 95 % confi-
dence interval ranging from 0.13 to 0.47 %. A greater
level of precision would be possible for PMR as it is
more common than GCA.
Analysis
Minimum cumulative prevalence estimates were calcu-
lated for both diseases. This method assumes that all
known cases are identified, those who have died within
the population are excluded and that non-responders to
the survey do not have the disease of interest. This
method also takes account of any deaths that have
occurred in both numerator and denominator popula-
tions, unlike cumulative incidence methods. Cumulative
prevalence estimates were expressed as a proportion;
confidence intervals were calculated based on the Pois-
son distribution.
Results
Database search
A total of 5,159 patients registered with the practice
were aged ≥55 years with a median age of 68 years. Of
these 2,706 (52.5 %) were female. Searching the elec-
tronic register identified 21 with GP-recorded GCA and
117 with GP-recorded PMR (Fig. 1 shows a flowchart
for the sampling method).
Survey
Subsequently, questionnaires were sent to 4,728 eligible
patients of the 5,159 registered with the practice to as-
certain any missed diagnoses of GCA and PMR not re-
corded in the GP electronic register. A total of 2,277
(48 % response rate) questionnaires were returned of
which 97.2 % had complete data. The respondents had a
median age of 70 years and 52 % were female. The age
and sex distribution of the non-responders was similar
to that of the responders (Table 3).
• 5,159 on GP list aged ≥ 55 years (median age 62.5 years, 52.5% female). List lock and mail merge 8th March 2013. 
• 117 had a GP record of PMR
• 21 had a GP record of GCA
• 4,728 eligible for suvery (median age 68.0 years, 53.6% female). Survery sent during March and April 2013.
• 2,277 responses (median age 70 years, 52% female). Includes remainder survey sent to non-responders in June 
2013.
• 124 attended clinical examination for potential of undiagnosed GCA or PMR, with an additional 36 undergoing 
telephone consultation.
Fig. 1 Flowchart of sampling method to generate cumulative prevalence estimates
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Clinical review of questionnaire respondents
A total of 15 individuals reported a diagnosis of GCA, 9
of whom were confirmed by the practice record. All 9
GP-recorded cases of GCA fulfilled the 1990 ACR classi-
fication criteria. In all cases the diagnoses were con-
firmed after referral to secondary care specialists
including rheumatologists, ophthalmologists, geriatri-
cians and neurologists. These subjects were not invited
for further clinical review.
Among the remaining 2,268 respondents who were
not already known from the GP-record as having a diag-
nosis of GCA or PMR, 31 reported the triad of visual
disturbance, scalp tenderness and symptoms suggestive
of jaw claudication. All these were contacted and, after
clinical review, none were thought to have GCA. At least
one symptom was reported in 1,007. Of these a sample
of 93 were reviewed, 25 had reported symptoms suggest-
ive of PMR without key features of GCA (i.e., lack of
headache, jaw claudication, visual disturbance or scalp
tenderness). After clinical review none were thought to
have undiagnosed PMR nor GCA. All those invited
attended for assessment. Table 3 lists the clinical charac-
teristics of the survey responders.
Of the 83 who reported a diagnosis of PMR on the
questionnaire, 73 cases were confirmed to have the con-
dition by the practice. The diagnoses of the two respon-
dents with both PMR and GCA were confirmed by
practice records.
Individuals reporting diagnoses of either GCA (n = 6)
or PMR (n = 10) but without confirmation on the GP
record were contacted by telephone. The discrepancy
was found to be either due to participants mistaking
arteritis for arthritis on the questionnaire, or to the diag-
noses being refuted by the GP later and withdrawn.
Case classification
Of the 21 cases identified in the GP record with GCA, a
total of 13 fulfilled the 1990 ACR classification criteria
set based on the information included in the GP record,
with a median age of 70 years at diagnosis and a mean
ESR of 74 mm/h. The remaining eight failed to fulfil
classification criteria based on their inflammatory
marker results and the absence of typical histological
findings on temporal artery biopsy; of these, six had in-
sufficient diagnostic information on their records having
changed practice.
There are five commonly used classification criteria
sets for PMR used in the previous published estimates.
All rely on the combination of typical clinical features,
age and elevated inflammatory markers but the cut-
points for these vary (Table 2).
Of the 117 cases identified in the GP records with
PMR, 73 (71 %) were female and the median age of
70 years. Inflammatory marker results, prior to steroid
initiation, were available for 100 patients (96 with ESR;
mean 45 mm/h, 33 with CRP; mean 50 mg/dL and 29
had both). Based on the data from these 100 individuals,
the estimated proportion of those satisfying the different
criteria sets are: 47 % (Bird); 62 % (Chuang); 62 %
(Healey); 62 % (Doran); and 79 % (Jones and Hazleman).
The majority (71 %) of PMR cases were managed exclu-
sively in primary care and no further information was
available for more detailed classification.
Table 3 Characteristics of survey responders
Characteristics Total
Population
Survey
Pool
Survey
Responders
PMR GCA
Self –reported Confirmed by GP Self –reported Confirmed by GP
Number ≥55 years 5,159 4,728 2,277 83 73 15 9
Age in years (median) 62.5 68.0 70.0 75.6 75.8 72.1 73.9
Percentage Female (%) 52.2 53.6 52.0 70.0 67.4 78.6 71.5
Clinical features reported
on questionnaire
Headache (%) 4.7 8.4 9.5 31.3 55.6
Jaw Pain (%) 7.5 20.5 19.2 31.3 44.4
Visual Disturbance (%) 19.8 22.9 24.7 37.5 44.4
Scalp Tenderness (%) 7.8 15.7 6.2 56.3 88.9
Shoulder Pain (%) 24.9 67.5 67.1 50 77.8
Myalgia (%) 18.8 68.7 67.1 43.8 55.6
Unexplained Weight
loss (%)
4.2 12.1 11 31.3 55.6
Migraine with aura (%) 15 14.6 16.7 18.8 11.1
No Symptoms (%) 55.8 20.5 21.9 18.8 0
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Prevalence estimates
Based on the cases which could be identified reliably
through GP record review (namely those who had
treatment with glucocorticoids and in whom the diag-
nosis that was not later refuted), the minimum cumula-
tive prevalence estimate for GP-diagnosed cases of
GCA was 0.41 % (95 % CI 0.23 %, 0.58 %) and for PMR
was 2.27 % (95 % CI 1.86 %, 2.67 %) (Table 4). The table
also shows age and sex specific cumulative prevalence
for both conditions.
The cumulative prevalence of GCA for those in whom
it was possible to apply the 1990 ACR classification cri-
teria retrospectively was 0.25 % (95 % CI 0.11 to 0.39).
Applying the various classification criteria retrospectively
to GP-diagnosed cases of PMR (Table 5) gave the follow-
ing cumulative prevalence estimates: Bird criteria 0.91 %
(95 % CI 0.65 to 1.17); Chuang, Healey and Doran criteria
1.20 % (95 % CI 0.90 to 1.50); and Jones and Hazleman
criteria 1.53 % (95 % CI 1.20 to 1.87).
Discussion
Principal findings
These are the first prevalence estimates for GCA and
PMR from a community sample in the UK for over
30 years and the first to apply contemporary classifica-
tion criteria. Our study was confined to single practice
in Norfolk, UK and faced challenges in applying existing
classification criteria retrospectively. However, a major
strength of the study was that every effort has been
made to ascertain cases of GCA and PMR which may
have not been known to the GP practice.
This study’s prevalence estimate for GCA is lower
than that reported in the 1985 UK community-based
study by Kyle et al. which examined 650 individuals
aged over 65 years from a single GP practice, screened
by questionnaire and those with possible GCA or
PMR assessed by a rheumatologist. After case record
review, eight cases fulfilled the existing criteria giving
a prevalence estimate for GCA of 1.23 % (95 % CI 0.38
to 2.08) [5], almost 5-fold higher than the present
study estimate. This excess is likely only to be partly
explained by the older age group (age > 65 vs > 55) and
their use of a lower ESR cut-off level (30 mm/h vs
50 mm/h). The UK prevalence ranges for PMR esti-
mated in the present survey (0.91 to 1.53 %) is similar
to that reported by Kyle et al. (1.69 % (95 % CI 0.70 to
2.68)) [5].
The wide variation in prevalence estimates for GCA
and PMR in more contemporary studies (Table 1) may
be due to differences in the methods used for selection
of cases; for example a number ascertained cases only
through secondary care or even tertiary referral centres
[19–21]. Definitions of disease also vary. Applying classi-
fication criteria sets rigorously in population studies of
these relatively rare diseases is logistically difficult as it
requires patient contact, laboratory tests results includ-
ing inflammatory markers and, for GCA, the results of
temporal artery biopsy. For these reasons contemporary
studies of GCA prevalence have largely relied on a
hospital-based assessments.
Data from Olmsted County Minnesota from the Roch-
ester epidemiology project have been used to calculate
prevalence based on cumulative incidence rates. GCA
cases (n = 173) were recorded in Olmsted County over a
50 year period (1950 to 1999) and PMR cases recorded
between 1970 and 1999, giving estimates of 0.23 and
0.74 % respectively. The estimates of incidence were age-
adjusted to the 1980 US white population. In 1980 in
Olmsted County there were 92,006 individuals (of whom
approximately 10 % were aged ≥50 years) recorded in the
Table 4 Cumulative prevalence estimate by sex and age bands based on GP records
Age Na Female Male PMR Female Male GCA Female Male
N Pr (95 % CI) N Pr (95 % CI) N Pr (95 % CI) N Pr (95 % CI) N Pr (95 % CI) N Pr (95 % CI)
55–60 978 500 478 1 0.10
(0.00, 0.30)
1 0.20
(0.00, 0.59)
0 1 0.10
(0.00, 0.30)
0 1 0.21
(0.00, 0.62)
60–69 1902 989 913 20 1.05
(0.59, 1.51)
15 1.52
(0.76, 2.28)
5 0.55
(0.07, 1.03)
3 0.16
(0.00, 0.34)
3 0.30
(0.00, 0.65)
0
70–79 1412 700 712 49 3.47
(2.52, 4.43)
33 4.71
(3.14, 6.28)
16 2.25
(1.16, 3.33)
6 0.43
(0.09, 0.76)
4 0.57
(0.01, 1.13)
2 0.28
(0.00, 0.67)
80–89 695 395 300 40 5.76
(4.02, 7.49)
20 5.06
(2.90, 7.22)
20 6.67
(3.84, 9.49)
9 1.30
(0.45, 2.14)
5 1.27
(0.16, 2.37)
4 1.33
(0.04, 2.63)
90–100 166 116 50 7 4.22
(1.16, 7.27)
5 4.31
(0.62, 8.01)
2 4.00
(0.00, 9.43)
2 1.72
(0.00, 4.09)
2 1.72
(0.00, 4.09)
0
100+ 6 6 0 0 N/A N/A 0 N/A N/A
Total 5159 2706 2453 117 2.27
(1.86, 2.67)
74 2.74
(21.12, 3.35)
43 1.75
(1.23, 2.27)
21 0.41 %
(0.23, 0.58)
14 0.52
(0.25, 0.79)
7 0.29
(0.07, 0.50)
Pr cumulative prevalence
aN total number of people registered with the practice
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US census and this rose to 144,248 (of who 45,325 (31 %)
were aged ≥50 years, 34,135 (24 %) were aged ≥55 years or
older and 25,037 (17 %) were aged ≥ 60 years) in 2010.
Since the incidence of both conditions increases with age
it is likely that the resultant derived prevalence estimates
will underestimate the true prevalence when age-adjusting
to a 1980 US average.
The lowest contemporary European estimate of GCA
prevalence (0.04 %) was generated by a 2014 German
study in which diagnoses were ascertained from hospital
insurance records. Record data have also been used in
two studies of GCA which have examined a UK GP elec-
tronic database, known as the Clinical Practice Research
Datalink (CPRD), but did not attempt to apply classifica-
tion criteria nor estimate prevalence [6, 22]. The study
by Petri et al. reported GCA incidence but estimated
prevalence for those aged ≥50 years as 0.33 % (personal
communication). Comparing our results to those of
Petri, we re-caculated the cumulative prevalence based
on the practice population aged ≥50 years. Since no per-
sons in the practice aged between 50 and 55 years had
been diagnosed with GCA this gave a cumulative preva-
lence of 0.34 % (95 % CI 0.20, 0.49), similar to that
found using the CPRD.
Studies of PMR have used a variety of classification
methods with a number developing study-specific cri-
teria for case recognition. For example, Bernatsky et
al. [23] identified cases through billing and hospitalisa-
tion; Doran et al. [9] developed their own classification
system. The present study shows that differences be-
tween existing classification sets, when applied to the
same population, may account for an almost two-fold
difference in prevalence estimates. The use of Bird’s
criteria set resulted in the lowest estimate. The Italian
MAPPING study also used these criteria and gener-
ated the lowest European estimate to date for PMR
prevalence [24].
In addition, four studies used cumulative incidence to
derive a prevalence estimate (Table 1). This method
assumes that the case mortality rate is comparable to
that of the general population. A number of studies have
shown GCA to be associated with an excess mortality
risk, particularly in the first two years after disease onset
[25, 26]. This may upwardly bias the prevalence esti-
mates in these studies. The mortality risk associated with
PMR is not firmly established. Left censoring in short-
term cumulative incidence studies (for example [19, 23])
might lead to an underestimate of prevalence.
Study limitations
Our estimates can only be applied to individuals aged
≥55 years. It should be noted that in our sample no
cases of GCA and only 5 % of GP-recorded cases of
PMR developed before the age of 55. The population
was White British and was restricted to one general
practice partnership in Norfolk and therefore the gener-
alisability of our results to more ethnically diverse re-
gions of the country or other countries is relatively
limited. The percentage of people aged ≥55 years in
Norfolk is 36 %. This is higher than the England and
Wales figure of 29 %. Given the older age of the Norfolk
population it is likely that both incidence and prevalence
estimates for GCA and PMR will be higher than in the
UK population as a whole. However this region of the
UK has provided epidemiological data for the Norfolk
Arthritis Register (NOAR) cohort and provided esti-
mates for the primary systemic vasculitides [27, 28].
Every effort was made to enrich the available clinical
data through both direct record review and question-
naire sampling, supplemented by clinical assessment.
While laboratory data were available in all cases of GP
recorded GCA, the results of tests of inflammatory
makers were missing in the clinical record in 15 % of
those assigned a GP diagnosis of PMR. Incomplete GP
records prevented us from confirming a diagnosis of
PMR where blood test results prior to the year 2000
could not be retrieved electronically. If the analysis is
confined only to those who responded to the question-
naire, prevalence estimates for GCA would be 0.19 %
Table 5 Cumulative prevalence estimates for cases which satisfy classification criteria applied to GP record data
Criteria set All Female Male
N Pr (95 % CI) N Pr (95 % CI) N Pr (95 % CI)
GCA (21 cases reported
in GP records)
Hunder 13 0.25 (0.11, 0.39) 9 0.33 (0.12, 0.55) 4 0.16 (0.00, 0.32)
PMR (117 cases reported
in GP records)
Bird 47 0.91 (0.65, 1.17) 28 1.04 (0.65, 1.42) 19 0.78 (0.43, 1.12)
Healey; Chuang; Doran 62 1.20 (0.90, 1.50) 39 1.44 (0.99, 1.89) 23 0.94 (0.56, 1.32)
Jones and Hazleman 79 1.53 (1.20, 1.87) 49 1.81 (1.31, 2.31) 30 1.22 (0.79, 1.66)
N total number of people identified in the practice. Pr: cumulative prevalence based on a total population of 5,159 (2,706 female, 2,453 male). Inflammatory markers
were available in 100 out of 117 GP record cases (of which 96 had ESR and 33 CRP with overlap of 29 cases with both CRP and ESR results at time of diagnosis)
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(95 % CI 0.07 % to 0.32 %) and for PMR would be
1.54 % (95 % 1.19 % to 1.90 %).
In designing the study, we were aware that no vali-
dated questionnaire exists for classification or diagnosis
of either GCA or PMR. A concern was that cases might
exist in the community, which had not been identified
by their GP. In the 1985 study by Kyle et al., one case of
GCA was identified which had been unknown to their
GP. Historical diagnoses are difficult to capture through
questionnaires, particularly in diseases that remit with
treatment. Cases that had entered remission before 2000
who were also not captured on the GP records may have
been difficult to detect in this study. However, by using
the combined approaches for case ascertainment in this
study, we feel it unlikely that we failed to capture cases
of undiagnosed or remitted disease. Our results suggest
that GP-recorded diagnoses are likely to encompass all
cases within a population, although not all will fulfil
classification criteria sets.
Conclusions
In conclusion we have provided the first contemporary
data on GCA and PMR in the UK for 30 years. These
conditions have been confirmed to be, respectively, the
most common forms of vasculitis and inflammatory
rheumatic disease in the UK and will become commoner
as the population ages since their peak incidence occurs
in individuals older than 70 years. Resources need to be
directed at managing these conditions and to understand
their aetiology with the aim of improving outcomes.
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